Advertisement

Topics

Latest "Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined" News Stories

08:50 EDT 25th September 2018 | BioPortfolio

Here are the most relevant search results for "Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined" found in our extensive news archives from over 250 global news sources.

More Information about Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined for you to read. Along with our medical data and news we also list Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined Clinical Trials, which are updated daily. BioPortfolio also has a large database of Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined Companies for you to search.

Showing "Saccharomyces Cerevisiae Strain Comparison Glucose Xylose Fermentations Defined" News Articles 1–25 of 2,400+

Tuesday 25th September 2018

IMFINZI® (durvalumab) is the First Immunotherapy to Demonstrate Significant Overall Survival Benefit in Unresectable, Stage III Lung Cancer

IMFINZI reduced the risk of death by nearly one-third compared to placebo in the Phase III PACIFIC trial Updated data reaffirm unprecedented improvement in progression-free survival of more than 11 months AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III ...


Horizon Pharma plc to Present 48-Week Follow-Up Analysis of the Teprotumumab Phase 2 Trial at the Annual Meeting of the American Thyroid Association

-- Horizon to host an investor call on Oct. 4 following the teprotumumab data presentation -- Horizon Pharma plc (NASDAQ: HZNP) will present new data on the 48-week follow up for the Phase 2 clinical trial evaluating teprotumumab for the treatment of moderate-to-severe active thyroid eye disease (TED). The data will be presented on Oct. 4, 2018, at the...

CesareanRates.org to publish state dashboards and track progress toward national low-risk cesarean birth rate

The Patient Safety Movement, a global non-profit working to eliminate preventable harm, applauds their efforts to reduce preventable deaths CesareanRates.org has published state dashboards to track progress toward the national low-risk cesarean birth rate target of 23.9 percent. This press release features multimedia. View the full release here: https://www.b...


AstraZeneca Ships FLUMIST® QUADRIVALENT Vaccine in the US for 2018-2019 Flu Season

Appropriate patients can receive the only needle-free, nasal spray flu vaccine from physicians as soon as late September AstraZeneca today announced the first shipment of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) doses in the US for the 2018-2019 influenza season. FLUMIST QUADRIVALENT, or the live attenuated influenza vaccine (LAIV), ...

GlycoMark®, Inc. Announces Partnership with Premier Medical Laboratory Services to Expand Diabetes Test Menu

GlycoMark has announced a partnership with Premier Medical Laboratory Services to increase the availability of the GlycoMark test, the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions in patients with diabetes. NEW YORK (PRWEB) September 25, 2018 GlycoMark®, Inc. has announced a partnership with Premier Medical Laboratory Services (PMLS) to ...

Brighter (BRIG) - Data-driven diabetes management as a service

Edison Investment Research - Pharmaceutical & healthcare - Brighter: Brighter is a healthtech company developing solutions for chronic diseases. Its initial strategy is the launch of Actiste, a mobile-connected glucose meter and insulin injection device for diabetes, which the company has submitted for CE certification. Its CE-marked cloud-based platform called the Benefit Loop and associated comp...

Slone Partners, Where People Are Our Science®, Announces Exclusive 2018 PMC Interview Series With Executives Who Sit On The Cutting Edge Of Personalized Medicine

Beginning October 2018, The Leading Healthcare Executive Search Firm Again Partners With Personalized Medicine Coalition To Interview 5 Industry Trailblazers BOSTON (PRWEB) September 25, 2018 Slone Partners, the leading executive search firm for life sciences, diagnostics and scientific healthcare companies, proudly announces the world-class roster of executives slated to be featured in its 2018 ...

Monday 24th September 2018

Global Orthotic Foot Insoles Market 2018-2022| Penetration of 3D Printing to Spur Growth| Technavio

The global orthotic foot insoles market 2018-2022 is expected to post a CAGR of close to 6% during the forecast period, according to the latest market research report by Technavio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005933/en/

Diabetic Retinopathy - A Drug Pipeline Analysis Report by Technavio

Technavio has announced their latest drug pipeline analysis report on diabetic retinopathy. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of dia

MedX Health Corp. Announces Board and Executive Changes

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces the following changes to its Board and Executive team, effective immediately. Scott Spearn, who joined the Company as President in April 2018 is taking on the additional role of Chief Executive Officer and is joining the Board of Directors. Rob von der Porten, previously the CEO, ha...

Ferring Pharmaceuticals Announces UK Launch of Testavan® (testosterone 2% gel) for the Treatment of Male Hypogonadism

West Drayton, England, UK – 24 September, 2018 – Ferring Pharmaceuticals today announced the launch of Testavan® 20 mg/g transdermal gel for the treatment of adult male hypogonadism. Testavan® is a new testosterone replacement therapy designed to restore testosterone levels to a normal range (300–1050 ng/dL) in adult males with hypogonadism. Male hypogonadism (or low...

Possible Molecular Pathway for Neurodegeneration in Prion Diseases Defined

NewsA new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

GeneCentric Therapeutics Licenses Pancreatic Cancer Subtyping Technology from University of North Carolina

Company will develop Pancreatic Cancer Profiler based on technology to identify drug responders for therapeutic development GeneCentric Therapeutics, Inc. today announced that the company has acquired an exclusive license from the University of North Carolina at Chapel Hill (UNC) to technology for subtyping Pancreatic Ductal Adenocarcinoma (PDAC). The ...

Global Gene Therapy Market 2018-2022| 22% CAGR Projection Over the Next Four Years | Technavio

Technavio analysts forecast the global gene therapy market to grow at a CAGR of over 22% during the forecast period, according to their latest market research report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005535/en/

Blue Cross and Blue Shield of Georgia Offers Innovative Virtual Diabetes Clinic for Consumers with Type 2 Diabetes

Blue Cross and Blue Shield of Georgia is taking an innovative approach to helping its consumers who have been diagnosed with Type 2 diabetes manage their condition to improve their health through a new virtual diabetes clinic with a smartphone app and monitoring tools. Participants in

ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018

ArQule, Inc. (Nasdaq:ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the Leerink Partners Roundtable Series on October 2, 2018, at 8:00am ET at the ...

ArQule to Present at the Cantor Global Healthcare Conference on October 1, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the Cantor Global Healthcare Conference on October 1, 2018, at 2:55pm ET at the InterContinental New York Barclay Hotel in New York City. The live webcast of the pres...

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

• First-to-market cell line-derived reference standard for myeloid blood cancers • Largest cell-line derived reference standard available, contains 22 mutations across 19 oncology-relevant genes • Enables faster, more reliable and more cost-effective assay validation Cambridge, UK, 24 September, 2018: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “t...

Sunday 23rd September 2018

A versatile system for fast screening and isolation of Trichoderma reesei cellulase hyperproducers based on DsRed and fluorescence-assisted cell sorting

In the biofuel industry, cellulase plays an indispensable role in hydrolyzing cellulose into fermentable glucose. Trichoderma reesei is a popular filamentous fungus with prominent ability to produce cellulase. Wh...

Oleaginicity of the yeast strain Saccharomyces cerevisiae D5A

The model yeast, Saccharomyces cerevisiae, is not known to be oleaginous. However, an industrial wild-type strain, D5A, was shown to accumulate over 20% storage lipids from glucose when growth is nitrogen-limited...

In this week’s Nature podcast: the ethics of sucking carbon-dioxide out of the atmosphere and bee swarms under strain https://go.nature.com/2prkKDX 

In this week’s Nature podcast: the ethics of sucking carbon-dioxide out of the atmosphere and bee swarms under strain https://go.nature.com/2prkKDX 

Saturday 22nd September 2018

Late-Breaking Clinical Study Results Demonstrate Exceptional Safety and Efficacy Outcomes for Resolute Onyx(TM) DES

TCT18: BIONYX Study Shows Strong Performance with Durable Polymer Resolute Onyx DES in Head-to-Head Comparison with Biodegradable Polymer DES DUBLIN and SAN DIEGO - September 22, 2018 - Investigators today unveiled new clinical data from the physician-initiated BIONYX study, representing the first all-comers analysis in nearly 2,500 patients comparing the safety and efficacy of th...

New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD

Novartis International AG / New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Pre-specified analysis provides insight into maintenance treatment effectiveness ...

Friday 21st September 2018

Genomic Study Brings Us Closer to Precision Medicine for Type 2 Diabetes

NewsAnalysis reveals disease's complexity, suggests potential clinical subtypes defined by genetics and physiology.Contributed Author:&nbs

Natural Antibiotic Shows Promise against Drug Resistant #TB Strain: http://ow.ly/D7Za30lUSRm pic.twitter.com/9fXJxeOb2L

Natural Antibiotic Shows Promise against Drug Resistant #TB Strain: http://ow.ly/D7Za30lUSRm  pic.twitter.com/9fXJxeOb2L


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks